Pricing Log in Create free account

BridgeBio Oncology Therapeutics, Inc (BBOT) vs Entrada Therapeutics, Inc. (TRDA)

BridgeBio Oncology Therapeutics, Inc and Entrada Therapeutics, Inc. are both Biotechnology companies. Entrada Therapeutics, Inc. is the larger, with a market value of $191.5M against $163.6M — 1.2× the size. BridgeBio Oncology Therapeutics, Inc has the higher net margin (0.00% vs −4,058.0%) and the higher return on invested capital (−127.7% vs −2,009.0%). Across the 12 metrics below, BridgeBio Oncology Therapeutics, Inc leads on 6 and Entrada Therapeutics, Inc. on 6.

Valuation

Metric BBOT TRDA Biotechnology median
P/E n/m n/m 10.60
P/S n/m 52.10 9.40
P/B 0.51 1.04 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.31 n/m 0.66
EV/Sales n/m 3.57 9.02
Earnings yield (135.29%) (78.53%) (32.88%)
Free cash flow yield (92.81%) (65.80%) (23.13%)

Profitability

Metric BBOT TRDA Biotechnology median
Gross margin — 100.00% 68.51%
Operating margin 0.00% (4,303.82%) 0.00%
Net margin 0.00% (4,057.98%) 0.00%
Free cash flow margin 0.00% (3,428.06%) 0.00%
Return on equity (252.10%) (59.88%) (51.96%)
Return on assets (96.69%) (47.48%) (46.06%)
Return on invested capital (127.66%) (2,008.96%) 0.00%

Growth

Metric BBOT TRDA Biotechnology median
Revenue growth (TTM) — (93.54%) 6.76%
EPS growth (last fiscal year) 99.93% (306.55%) 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric BBOT TRDA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.69 7.85 4.97
Net debt to EBITDA 2.93 1.88 1.01

Dividend

Metric BBOT TRDA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric BBOT TRDA Biotechnology median
Market cap 163.56m 191.45m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack